Stratec SE (SBS)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 23.00 |
|---|---|
| 52-week range | 16.30 – 26.70 |
| Return, 1 month / 3 months | +0.9% / +14.7% |
| Return, 1 year / 3 years | −7.6% / −36.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 49 |
| Volatility (1 year) | 41.1% |
| Worst drawdown (1 year) | -33.7% |
| Average daily value traded | 0.28M EUR |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Stratec SE designs and builds automated instrument systems used in laboratory diagnostics. The company develops sample handling and analysis equipment for in-vitro diagnostics, supplying diagnostics companies and clinical laboratories that need reliable automation for testing. Its work covers the engineering, production and integration of these instruments, often tailored to the requirements of its customers. Stratec is based in Birkenfeld, Germany, and serves customers in the diagnostics and life-science markets.
The shares are listed on the Deutsche Börse Xetra in Germany under the code SBS, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Stratec SE (SBS) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 23.00 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 217 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.6% and over the last three months it rose 14.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 82 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.2% | ||
| From 52-week high | -10.7% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 14.7% | ||
| 6-month return | 28.1% | ||
| 12-month return, skipping the last month | -8.4% | ||
| Stability (higher is calmer) | 41 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.7% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.28M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 51 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | +0.9% |
| 3 months | +14.7% |
| 6 months | +28.1% |
| 1 year | −7.6% |
| 3 years | −36.2% |
| 5 years | −80.6% |
Signals
| 50-day / 200-day average | 23.31 / 19.80 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Jun 2026 | EUR 0.6000 |
| 30 Jun 2025 | EUR 0.6000 |
| 20 May 2024 | EUR 0.5500 |
| 18 May 2023 | EUR 0.9700 |
| 23 May 2022 | EUR 0.9500 |
| 21 May 2021 | EUR 0.9000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.